A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).
Trial Details
- NCT ID
- NCT07452198
- Phase
- PHASE3
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Status
- RECRUITING
- Cancer Type
- Multiple Myeloma
- Interventions
- GR1803 injection
- Daratumumab
- Pomalidomide
- Dexamethasone
- Locations (sample)
- Tianjin, China|39.14222,117.17667
Key Eligibility Criteria
- Have an eastern cooperative oncology group (ECOG) performance status score of 0, 1, or 2 at screening and baseline.
- Diagnosed as multiple myeloma according to the diagnostic criteria of the International Myeloma Working Group (IMWG) diagnostic criteria.
- Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide; a. participants who have received only…
- Documented evidence of progressive or stable disease based on investigator's determination of response by IMWG criteria on or after their last regi…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Multiple Myeloma Trials on Trialify →